Applications Open: CSIRO ON Prime
Posted: 23 November Closes: 17 February 2023 ON Prime is a free program designed to help research teams of two to five people take their projects to the next level through customer discovery activities and more. We work…
2022 BioMelbourne Network Annual General Meeting wrap
Posted: 18 November 2022 The 2022 BioMelbourne Network Annual General Meeting and Networking Event was held on Thursday 17 November in person and online. Honorary Life Membership awards BioMelbourne Network bestows Honorary Life Membership awards to Members whose…
4DMedical Debuts “XV Scanner,” Most Advanced Lung Scanning Technology in Decades At RSNA
Posted: 18 November 4DMedical will unveil the “XV Scanner,” a breakthrough lung scanning device that integrates fluoroscopy with advanced analytics software at the 2022 annual meeting of the Radiological Society of North America (RSNA) in Chicago. The XV…
Phase 2 trial of ChulaCov19 BNA159 mRNA Vaccine to start in Australia
Posted: 18 November ChulaCov19 BNA159 is a COVID-19 mRNA vaccine developed by Chulalongkorn University and produced by BioNet • ChulaCov19 mRNA vaccine was found safe and immunogenic for primary immunization in clinical trials in Thailand. • The Australian…
ARCS Signature Program
Posted: 16 November 2022 Closes: 13 February 2023 The ARCS Signature Program is designed for senior executives and emerging leaders who are working in the med tech, biotech and pharmaceutical sectors. This includes those who are part of…
Backing business events to support jobs and innovation
Posted: 15 November The City of Melbourne has doubled its funding to support conferences, workshops and other business events – bringing more people together to drive innovation and boost the economy. An augmented reality festival, sustainable tech pitch…
Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC
Posted: 11 November Immutep Limited, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announced compelling new clinical data from the TACTI-002 all-comer PD-L1 Phase II trial evaluating Immutep’s lead product candidate, eftilagimod alpha…
Researchers make strides in the fight against COVID-19
Posted: 9 November New research from the Peter Doherty Institute of Infection and Immunity (Doherty Institute), The University of Melbourne and WEHI has unlocked key information in our understanding of molecular immune responses to COVID-19. Following COVID-19 infection,…
Virus discovery could help fight cancer
Posted: 9 November In a world first, La Trobe University researchers have discovered a virus that attacks a prominent disease-causing bacterium – a “ringleader” that recruits harmful bacteria to cause periodontitis, and potentially helps cancer grow and spread.…
Peter MacCallum Cancer Centre and Cartherics Announce Collaboration to Develop Autologous CAR-T Cell Therapy for Cutaneous T-Cell Lymphoma
Posted: 8 November The Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced that they have entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-001) for the…
Monash and Hudson Institute teams’ world-first for newborns
Posted: 4 November Melbourne scientists have discovered a way to treat seizures in newborns that will not only help protect their developing brain from further injury, but may also provide the first new, safe and effective treatment in decades.…
